Thus, Azeliragon is currently being evaluated in two clinical trials, (1) in MGMT unmethylated Glioblastoma (NCT05986851), and (2) in combination with chemoradiotherapy in newly diagnosed Glioblastoma (NCT05635734). This evidence concerns the gene MGMT and glioblastoma.